Applications of DL-Alanyl-DL-Leucine in Industrial Manufacturing

DL-Alanyl-DL-Leucine, a dipeptide raw material produced through advanced synthesis techniques in our facility, serves multiple specialized downstream industries including pharmaceutical formulation, peptide-based nutritional manufacturing, customized diagnostic reagent production, and selected biotechnological fermentation processes. Below we detail specific industrial scenarios where this compound plays a defined functional role.

1. Peptide Synthesis for Pharmaceutical Actives

In the pharmaceutical sector, companies incorporate DL-Alanyl-DL-Leucine as a key protected fragment during the stepwise solid-phase or solution-phase peptide synthesis of generic or custom APIs. Its standardized purity and side-chain compatibility allow seamless insertion into peptide chains, supporting production of non-commercial peptide analogs, research-grade APIs, and intermediates for regulatory filings. Manufacturers require strict compliance with pharmacopeial and cGMP regulations to guarantee traceability and batch-to-batch consistency. The inclusion level is highly calculated based on the sequence design and expected yield efficiency, with small buffer margins set according to downstream purification and coupling reaction success rates. Intermediate APIs produced using this dipeptide undergo subsequent deprotection, extension, and final cyclization or conjugation, after which final purification for regulatory testing proceeds via preparative chromatography or lyophilization.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.)
• USP–NF General Chapter (where applicable)
• FDA 21 CFR Part 210/211 for drug substance production

Typical usage ratio

• 0.5–4.0 molar equivalents per coupling step; precise ratio determined by target peptide length and excess required for complete coupling

Downstream process integration

• Added at protected amino acid loading stage or repetitive chain elongation cycles during SPPS/Liquid-phase synthesis; integration point defined by sequence specificity and protection group compatibility

Final product types

• Peptide-based APIs (active pharmaceutical ingredients)
• Research peptides and custom-sequence intermediates
• Reference standards for analytical laboratories
• Small-molecule–peptide conjugates for preclinical testing

2. Diagnostic Peptide Reagent Manufacturing

Leading diagnostic reagent manufacturers rely on DL-Alanyl-DL-Leucine for the synthesis or stabilization of peptide substrates utilized within enzyme activity measurement kits and immunoassays. The dipeptide acts as either a specific substrate fragment in peptide-based test strips or as a coupling standard for reference calibrators. Rigorous quality criteria demand conformity with ISO standards for diagnostics and validation according to clinical chemistry guidelines, especially for products entering regulated markets. The working concentration typically varies with the target enzyme and sensitivity of the detection system, so usage ratios are tailored during validation batches. The raw material is incorporated into automated or manual peptide assembly operations as well as final reagent blending just prior to kit packaging or QC release.

Industry compliance standards

• ISO 13485:2016 Medical Devices—Quality Management
• CLSI protocols (e.g., EP5-A2 for Evaluation of Precision)
• CE IVDR (In Vitro Diagnostic Regulation) for EU market
• FDA 21 CFR 820 for medical device controls (U.S. market)

Typical usage ratio

• 0.01–0.2% (w/w) within peptide-based substrates or buffer formulations, adjusted based on assay detection limit and enzymatic turnover rate

Downstream process integration

• Dosage portioned into substrate synthesis reactors or blended directly into liquid calibration reagent batches during final kit assembly stages

Final product types

• Enzyme activity assay kits
• Immunodiagnostic peptide standards
• Point-of-care diagnostic test strips
• Clinical calibration solutions for biochemistry analyzers

3. Specialty Nutrition Ingredient Preparation

Producers of medically oriented nutrition, such as clinical enteral formulas or athletic peptide supplements, utilize DL-Alanyl-DL-Leucine as a digestible dipeptide source to enhance nitrogen uptake and promote rapid assimilation. It is favored in formulations designed for compromised digestion or as part of amino acid profiling in research-backed performance products. Regional food additive rules and product labeling regulations define allowable entry points and documentation requirements—the ingredient often undergoes full traceability audits. Process engineers generally incorporate the dipeptide in mixing tanks ahead of thermal treatment or sterile filtration, with the ratio varying by intended protein fortification target and the patient or athlete demographic. Finished batches are subsequently portioned into ready-to-drink, powder, or reconstitutable medical product lines.

Industry compliance standards

• EU Regulation (EC) No 1333/2008 on food additives
• FDA 21 CFR Part 170—Food Additives
• ISO 22000 (Food Safety Management Systems)
• China GB 29924 or equivalent national standards for special amino acid ingredients

Typical usage ratio

• 0.05–0.3% (w/w) in clinical nutrition blends; range adjusted according to formula protein content, patient tolerance, and intended amino acid composition

Downstream process integration

• Blended into protein hydrolysate or amino acid premix during slurry preparation, then thermally processed or filtered before final bottling or powdering

Final product types

• PEPTIDE-based clinical nutrition drinks
• Tube feeding powders for medical nutrition therapy
• Athletic performance peptide supplementations
• Specialty infant or elderly nutrition formulas

4. Bioprocessing Fermentation Additive

Within selected microbial and cell culture fermentation applications, DL-Alanyl-DL-Leucine serves as a defined nitrogen or peptide fragment source, enhancing peptide expression or as an experimental control in metabolism studies. Producers must meet international standards for additives in bioprocessing and maintain full batch traceability in cGMP-compliant environments. Operations determine the addition level based on strain requirements, fermentation scale, and target peptide productivity, typically optimizing through pilot series runs prior to commercial campaigns. The dipeptide is charged into nutrient feed reservoirs or directly dosed into bioreactors during inoculation or growth phases. End-use applications typically relate to high-value specialty peptide or biopharma ingredient production, or to proprietary research platforms where nitrogen supply impacts expression characteristics.

Industry compliance standards

• ICH Q5D Biotech Product Quality of Peptides and Proteins
• ISO 9001 for bioprocess manufacturing operations
• EudraLex Volume 4 GMP Annex 2 for biologics processes
• FDA 21 CFR 600-680 for biological products (as applicable)

Typical usage ratio

• 0.02–0.15% (w/v) in fermentation media, tuned in response to cell density development and product titer during process scale-up stages

Downstream process integration

• Dosed into culture media reservoir ahead of inoculation or as a continuous feed throughout fermentation, contingent upon the bioreactor mode and titration feedback from in-process analytical monitoring

Final product types

• Recombinant peptide pharmaceuticals (post-purification)
• Bioactive peptide research platforms
• Cell culture–produced research-grade fractions
• Fermentation-derived specialty peptides for industrial R&D use